Clinical Studies & Research

Dr. Cox completed work for this study “A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines” serving as the principal investigator.

Dr. Cox has completed work as the principal investigator for this multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition. This study began in November 2018 and ended in April 2021.

Dr. Cox completed work as the principal investigator on this multicenter, single-blind, randomized, controlled study of the safety and effectiveness of JUVÉDERM
VOLUMA® XC injectable gel for cheek augmentation using a cannula. Dr. Cox has long been an advocate for the safety and effectiveness of injecting with the use of a cannula rather than just a needle in the mid-face. This study began in February of 2018 and finished in October of 2018.

Dr. Cox has completed work as principal investigator for this study “A Multicenter, Single-Blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLBELLA for Correction of Infraorbital Hollowing.” Dr. Cox was pleased with the beautiful, natural results achieved. This study began in February 2018 and ended in October 2019.

Dr. Cox has completed work as principal investigator for this study “A Randomized, Controlled, Evaluator-Blinded, Multi-Center Study to Evaluate the Effectiveness and Safety of Restylane Kysse versus a Control in the Augmentation of Soft Tissue Fullness of the Lip.” Dr. Cox found this new product to be unique and effective, and we’re excited to now have Restylane Kysse as a treatment option for patients. This study began in November 2017 and ended in June of 2019.

Dr. Cox finished work as the principal investigator for this study “A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study on the Safety and Pharmacodynamic Response of BOTOX in Subjects with Moderate to Severe Dynamic Glabellar Lines.” The study evaluated tweaks in the treatment of moderate to severe glabellar lines (those vertical lines between the brow).  Dr. Cox enjoyed looking at an existing product with a new perspective. This study began in November of 2017 and ended in March of 2019.

Dr. Cox completed work as principal investigator in this follow-up to a recently completed study.  The follow-up “An Open Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of [product] for Injection for Treatment of Moderate to Severe Glabellar Lines” is an unblinded study with multiple treatments.   This new, Botox-like product is seeking registration for treatment of vertical lines between the eyebrows, and may eventually be the sixth injectable used to treat facial wrinkles and lines.  Each will be unique in some way, patients working with skilled injectors will benefit from the ability to match product characteristics to individual anatomy. It’s an interesting time in aesthetic medicine!   This study started in June 2017 and ended in December 2018.

Dr. Cox recently completed work as principal investigator for the study “A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of [product] for Injection to Treat Moderate to Severe Glabellar Lines”  This is another new, Botox-like product seeking registration for treatment of vertical lines between the eyebrows.  This is the third new product in as many years looking to displace market leader Botox in the treatment of facial lines.  Adding already registered Dysport and Xeomin to the mix means we’ll eventually have six (or more) injectables for treating facial lines.  Each of the products is unique in some way, and we’ve really enjoyed working with the manufacturers to identify which patients will most benefit from the characteristics of their product.  It’s an interesting time in aesthetic medicine!   This study began in November 2016 and just finished in December 2017.

Dr. Cox is serving as principal investigator in the study “Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of [product] in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study.” This study is evaluating a new Botox-like product for treatment of vertical lines between the eyebrows.  We expect this will come to market in the next year or so.  As companies develop similar products with slightly different characteristics, there’s opportunity for skilled injectors to tailor treatments by selecting products best matched to an individual’s unique facial anatomy.  It’s customized aesthetic medicine and we’re excited about the possibilities.  The study began in October 2016 and is nearing completion.

Dr. Cox was a site clinician for the study “Qualitative Work on the Facial Lines Satisfaction Questionnaire (FLSQ) in Select Age Groups.”   This work continued the development of tools to assess patient satisfaction with treatment of facial lines.  In this case we applaud Allergan for supporting objective measurement of patient satisfaction.  Although we know the products work long before they come to market, the proof is whether patients agree once they’re out and in use.  The study was performed August through December 2016.